Five IPOs debuted this week, and raised over $1.3 billion in proceeds. One SPAC also listed. One name that did not join the fray was aluminum company Novelis (NVL), which called off its planned $878 million IPO at the eleventh-hour. Three IPOs...read more
Biotech IPOs needed a win, and they got one on Friday with Rapport Therapeutics (RAPP). After two months without a biotech IPO, Rapport priced its offering at the midpoint to raise $136 million, and traded up 22.4%. ...read more
Rapport Therapeutics, a Phase 2-ready biotech developing small molecule therapies for CNS disorders, raised $136 million by offering 8 million shares at $17, the midpoint of the $16 to $18 range. The company planned to raise an additional $18 million in a...read more
Rapport Therapeutics, a Phase 2-ready biotech developing small molecule therapies for CNS disorders, announced terms for its IPO on Monday. The Boston, MA-based company plans to raise $136 million by offering 8 million shares at a price range of $16 to $18. It...read more
US IPO Weekly Recap: Healthcare software leads $1.3 billion IPO week, even as Novelis calls off IPO
Five IPOs debuted this week, and raised over $1.3 billion in proceeds. One SPAC also listed. One name that did not join the fray was aluminum company Novelis (NVL), which called off its planned $878 million IPO at the eleventh-hour. Three IPOs...read more
A good rapport: Rapport Therapeutics rises 22% in IPO, reopening the door for biotech listings
Biotech IPOs needed a win, and they got one on Friday with Rapport Therapeutics (RAPP). After two months without a biotech IPO, Rapport priced its offering at the midpoint to raise $136 million, and traded up 22.4%. ...read more
CNS disorder biotech Rapport Therapeutics prices IPO at $17 midpoint
Rapport Therapeutics, a Phase 2-ready biotech developing small molecule therapies for CNS disorders, raised $136 million by offering 8 million shares at $17, the midpoint of the $16 to $18 range. The company planned to raise an additional $18 million in a...read more
CNS disorder biotech Rapport Therapeutics sets terms for $136 million IPO
Rapport Therapeutics, a Phase 2-ready biotech developing small molecule therapies for CNS disorders, announced terms for its IPO on Monday. The Boston, MA-based company plans to raise $136 million by offering 8 million shares at a price range of $16 to $18. It...read more